IMI Members

EU Logo efpia logo

Future Topics

The following topics are under consideration for inclusion in future Calls for proposals to be launched under IMI 2:

  • Patient perspective elicitation on benefits and risks of medicinal products, supplementing benefit risk assessments by regulators and HTAs (health technology assessments) from development through the entire life cycle
  • Development of a quantitative system toxicology (QST) platform
  • Diabetic kidney disease (DKD) biomarker idea
  • Inflammation and Alzheimer’s disease (AD): modulating microglia function – focussing on TREM2 and CD33
  • Enabling magnetic encephalography (MEG) as a biomarker for diagnosis and disease progression in mild cognitive impairment (MCI) and Alzheimer’s disease (AD)
  • Understanding the role of amyloid biomarkers in diagnosis, clinical management and treatment of patients with cognitive impairment
  • Evolving models of patient engagement and access for earlier identification of Alzheimer’s disease
  • Bringing apolipoprotein E (APOE) biology to validated Alzheimer’s disease targets

All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be communicated after approval by the IMI Governing Board.